

**Remarks/Arguments**

Applicants have amended the specification to provide the priority claim. The claims have been amended to remove multiple dependencies and to otherwise place the claims in an appropriate U.S. format.

Certain new claims have been added:

- Claim 15. Basis for this claim is to be found in original claim 4.
- Claim 16. Basis for this claim is to be found in original claim 5.
- Claim 17. Basis for this claim is to be found in original claim 6.
- Claim 18. Basis for this claim is to be found in original claim 9.
- Claim 19. Basis for this claim is to be found in original claim 12.
- Claim 20. Basis for this claim is to be found in original claim 12.
- Claims 21-23. Basis for these claims is to be found in the specification on page 5 lines 7-11 of the published PCT specification.

No new matter has been added by these amendments.

The above amendments have been made without prejudice to Applicants right to prosecute any cancelled subject matter in a timely filed continuation application.

Applicants believe the application is in condition for allowance, which action is respectfully requested.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 101213-1P US.

Respectfully submitted,



---

Name: Lucy C. Padget  
Dated: February 23, 2006  
Reg. No.: L0074  
Phone No.: 781-839-4182  
Global Intellectual Property, Patents  
AstraZeneca R&D Boston  
35, Gatehouse Drive  
Waltham, MA 02451